Nemes Laszlo Nuvalent (NASDAQ:NUVL) recently publicized that the FDA gave NVL-655 their Breakthrough Therapy Designation (BTD) for locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC). The BTD press release encouraged me to do some preliminary research on Nuvalent and NVL-655. It didn't take me long to determine that NVL-655 has the potential to be a vital therapy for ALK+ NSCLC patients who often have to deal with multiple lines of therapy after their cancer develops resistance to targete ...